GMP IPO Watch
List of all live and open IPOs today. Check subscription status, price bands, and lot sizes for active Mainboard and SME issues.
Real-time grey market premium for every open and upcoming IPO, updated through the day on our sister site.
Open IPO
One of India’s top 3 basmati rice exporters, Amir Chand Jagdish Kumar, enters Day 3 of its ₹440 crore IPO. With a price band of ₹201–₹212 and a ₹7 GMP, the issue is already oversubscribed. We dive into the "Aeroplane" brand's strength, the subscription numbers, and whether the 43% EBITDA growth makes this a "Subscribe."
Open IPO
Jaipur’s Emiac Technologies launches its ₹31.75 crore SME IPO on March 27, 2026. With a massive 269% revenue jump last year and a high-margin AI-content model, we dive into the ₹93–₹98 price band, the anchor investor buzz, and whether this digital powerhouse is a "Subscribe" for your portfolio.
Open IPO
Navi Mumbai’s Vivid Electromech is currently in the middle of its ₹130.54 crore IPO. Specializing in high-voltage and low-voltage electrical panels, the company has seen its profits jump 400% in just two years. We look at the Day 2 subscription trends, the ₹555 price band, and why the "Data Center" boom is their biggest tailwind.
Open IPO
Hyderabad-based Sai Parenteral's enters the final stretch of its ₹409 crore IPO. With a price band of ₹372–₹392 and a focus on high-margin injectables, the company is pitching a massive growth story. However, with a ₹0 GMP and a high P/E ratio, we break down the Day 3 subscription and the "Long-Term vs. Listing Gain" debate.
Open IPO
Get the final day update on Tipco Engineering India Limited’s SME IPO. Check the latest Grey Market Premium (GMP), real-time subscription status, allotment dates, and whether you should subscribe on the closing day.
Open IPO
Navi Mumbai-based Vivid Electromech opens its ₹130.54 crore IPO today with a price band of ₹528–₹555. Boasting a massive 74% CAGR and partnerships with giants like Schneider and ABB, this electrical panel manufacturer is aiming for a 3x capacity expansion. We analyze the Day 1 subscription and the company's long-term "moat."
Open IPO
Mumbai-based Highness Microelectronics enters Day 2 of its ₹21.67 crore IPO with a price band of ₹114–₹120. With a ₹20 GMP (16% estimated gain) and a massive shift into the high-margin Defense and Railway sectors, we break down the subscription numbers and whether this niche display manufacturer fits your portfolio.
Open IPO
Hyderabad-based Sai Parenteral's enters Day 2 of its ₹409 crore IPO with a price band of ₹372–₹392. While Day 1 saw a muted 0.05x subscription and a flat ₹0 GMP, the company’s recent Australian acquisition and strong anchor book (including Morgan Stanley) suggest a long-term story. We break down the financials and the "Noumed" factor.
Open IPO
The ₹440 crore IPO of Amir Chand Jagdish Kumar (Exports) is seeing robust demand, having already crossed the 1x mark on its first day. With the price band set at ₹201–₹212 and a ₹7 GMP, we look at why Non-Institutional Investors (NIIs) are rushing in and whether the "Three Star Export House" status makes this a long-term winner.
Open IPO
The ₹440 crore IPO of Amir Chand Jagdish Kumar (Exports) launched today, March 24, 2026, with a price band of ₹201–₹212. A 100% fresh issue, the company is leveraging its iconic "Aeroplane" brand to fuel a massive working capital push. We look at the 29% revenue growth, the current ₹6 GMP, and whether this "Three Star Export House" fits your portfolio.
Open IPO
The ₹21.67 crore IPO of Highness Microelectronics launched today, March 24, 2026, with a price band of ₹114–₹120. Operating in the specialized "rugged display" market for medical and defense sectors, the company is looking to fund a new assembly line in Mumbai. With a current GMP of ₹10 (8% gain), we analyze if this SME issue is a "buy" for your portfolio.
Open IPO
Hyderabad-based Sai Parenteral's Limited launched its ₹409 crore IPO today, March 24, 2026, with a price band of ₹372–₹392. With a bold move to acquire Australia’s Noumed Pharmaceuticals, the company is shifting from a domestic manufacturer to a global CDMO powerhouse. We analyze the 72x P/E valuation, the flat GMP, and the long-term potential of this injectable specialist.